Live feed
·
PRReleasevia Quantisnow
SELLAS Life Sciences Group Inc. logo

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

ByQuantisnow·Wall Street's wire, on your screen.
SLS· SELLAS Life Sciences Group Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLS (SELLAS Life Sciences Group Inc.) and more on Quantisnow.